The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
106 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $21,658,060 in first-year total cost, median $204,185.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-X (O1)]12
- Special Emphasis Panel[ZCA1 SRB-A (O1)]9
- Special Emphasis Panel[ZCA1 SRB-K (O1)]9
- Special Emphasis Panel[ZCA1 SRB-P (O1)]7
- Special Emphasis Panel[ZCA1 SRB-X (M2)]6
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR7
- DUKE UNIVERSITY5
- FRED HUTCHINSON CANCER RESEARCH CENTER4
- UNIVERSITY OF VIRGINIA4
- BAYLOR COLLEGE OF MEDICINE3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Raman-enhanced spectroscopy (RESpect) for anal dysplasia in HIV-positive patients1R21CA244078-01 | AGSALDA-GARCIA, MELISSA ANNE | UNIVERSITY OF HAWAII AT MANOA, HI | $400,414 | ZCA1 |
| 2020 | Radiotherapy-associated breast cancer: machine learning on genotypes to predict individualized risk1R21CA234752-01A1 | BERNSTEIN, JONINE L.OH, JUNG HUN | SLOAN-KETTERING INST CAN RESEARCH, NY | $293,870 | ZCA1 |
| 2020 | Development of a new molecular predictor for risk of distant metastases in melanoma1R21CA245577-01 | HOLMEN, SHERI L | UNIVERSITY OF UTAH, UT | $249,528 | ZCA1 |
| 2020 | Pathogenic mechanisms of sinonasal sarcoma, a novel gender dimorphic cancer1R21CA234829-01A1 | CHOU, MARGARET MARY | CHILDREN'S HOSP OF PHILADELPHIA, PA | $246,840 | ZCA1 |
| 2020 | Therapeutic vulnerabilities associated with PTEN missense mutations1R21CA245337-01 | CHAREST, ALAIN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $245,438 | ZCA1 |
| 2020 | Cryo-EM analysis of PI3K signaling complexes in glioblastoma1R21CA245631-01 | KELLY, DEBORAH FSHENG, ZHI | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $240,804 | ZCA1 |
| 2020 | High-Dimensional Profiling of Physiological Signaling Responses to Identify Relapse-Driving Cells in Acute Myeloid Leukemia1R21CA234529-01A1 | REDELL, MICHELE S. | BAYLOR COLLEGE OF MEDICINE, TX | $236,030 | ZCA1 |
| 2020 | Tissue-based predictive biomarkers for Cabozantinib therapy in metastatic renal cell carcinoma1R21CA238053-01A1 | CHOUEIRI, TONISIGNORETTI, SABINA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $234,596 | ZCA1 |
| 2020 | Saturation genome editing approach to functionally test all possible MSH2 variants1R21CA237920-01A1 | COTNEY, JUSTIN LEEHEINEN, CHRISTOPHER D. | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $230,010 | ZCA1 |
| 2020 | Targeting the Unique Paracaspase MALT1 to Overcome Ibrutinib Resistance in Relapsed/Refractory MCL Patients1R21CA237969-01A1 | JIANG, CHANGYINGWANG, MICHAEL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2020 | 3D Multi-Contrast MRI with Automatic Brain Tissue and Lesion Segmentation1R21CA238137-01A1 | LIU, JINGLUPO, JANINE MARIE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $225,686 | ZCA1 |
| 2020 | Enhancing Breast Tumor Cell Immunogenicity by Targeting the Epigenetic Factor NURF1R21CA245455-01 | LANDRY, JOSEPH WILLIAM | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $225,589 | ZCA1 |
| 2020 | Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant and neuroendocrine prostate cancer1R21CA245595-01 | BROOKS, JAMES D. | STANFORD UNIVERSITY, CA | $221,808 | ZCA1 |
| 2020 | Interruption of squalene epoxidase and DNA damage response in cancer therapy1R21CA245590-01 | ZHANG, JUNRAN | OHIO STATE UNIVERSITY, OH | $218,790 | ZCA1 |
| 2020 | Artificial Intelligence driven prediction of brain metastasis from primary tumor sites at diagnosis1R21CA245597-01 | MERAJVER, SOFIA DIANA | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $218,790 | ZCA1 |
| 2020 | CXCL12/CXCR4 regulation of PI4KIIIalpha activity in metastatic prostate tumors1R21CA235541-01A1 | CHINNI, SREENIVASA R | WAYNE STATE UNIVERSITY, MI | $215,985 | ZCA1 |
| 2020 | Identify tumor suppressor driver genes of pancreatic ductal adenocarcinoma1R21CA245437-01 | WANG, PEI | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $215,985 | ZCA1 |
| 2020 | Memory-like NK cells for enhanced immunotherapy of post transplant relapse in patients with myeloid malignancies1R21CA245413-01 | ROMEE, RIZWAN | DANA-FARBER CANCER INST, MA | $206,869 | ZCA1 |
| 2020 | CAR T-Cell Therapy Targeting the Membrane-Proximal C2-Set Domain of CD33 for Treatment of Acute Myeloid Leukemia and Other CD33-Expressing Hematopoietic Neoplasms1R21CA245594-01 | WALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $205,700 | ZCA1 |
| 2020 | Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and Venetoclax1R21CA237939-01A1 | TANG, DEAN G. | ROSWELL PARK CANCER INSTITUTE CORP, NY | $204,181 | ZCA1 |
| 2020 | Cherenkov imaging of Total Skin Electron Therapy (TSET)1R21CA239127-01A1 | ZHU, TIMOTHY C. | UNIVERSITY OF PENNSYLVANIA, PA | $201,362 | ZCA1 |
| 2020 | Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine1R21CA245560-01 | YADDANAPUDI, KAVITHA | UNIVERSITY OF LOUISVILLE, KY | $200,970 | ZCA1 |
| 2020 | Novel molecular agents targeting NF-κB c-Rel O-GlcNAcylation for the treatment of acute myeloid leukemia.1R21CA246194-01 | PARAMESWARAN, RESHMIRAMAKRISHNAN, PARAMESWARAN | CASE WESTERN RESERVE UNIVERSITY, OH | $195,752 | ZCA1 |
| 2020 | Tumor-specific activation of transgene expression by Scd3 locus1R21CA245602-01 | NAKANISHI, MASAKO | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $191,675 | ZCA1 |
| 2020 | Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccine1R21CA234516-01A1 | HUNG, CHIEN-FU | JOHNS HOPKINS UNIVERSITY, MD | $191,383 | ZCA1 |
| 2020 | Regulation of autophagy in bone metastasis1R21CA245609-01 | PRATAP, JITESH | RUSH UNIVERSITY MEDICAL CENTER, IL | $183,494 | ZCA1 |
| 2020 | Characterization of EPHA3 intragenic rearrangements in high-grade serous carcinoma progression and recurrence1R21CA237964-01A1 | WANG, XIAOSONG | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $182,909 | ZCA1 |
| 2020 | Improving immunotherapies to melanoma through modulation of MAIT cell activation by the microbiome1R21CA245432-01 | GAPIN, LAURENTLOZUPONE, CATHERINEMCCARTER, MARTINMEDINA, THERESA M | UNIVERSITY OF COLORADO DENVER, CO | $181,741 | ZCA1 |
| 2020 | At home monitoring for 177Lu DOTATATE treatment personalization1R21CA237788-01A1 | MIYAOKA, ROBERT S | UNIVERSITY OF WASHINGTON, WA | $181,741 | ZCA1 |
| 2020 | Determining the cell of origin in Ewing sarcoma through genomic analysis1R21CA237789-01A1 | SPECTOR, LOGAN G.WEBBER, BEAU RICHARD | UNIVERSITY OF MINNESOTA, MN | $179,988 | ZCA1 |
| 2020 | Growth hormone actions in prostate carcinogenesis1R21CA238105-01A1 | MARKER, PAUL C | UNIVERSITY OF WISCONSIN-MADISON, WI | $171,242 | ZCA1 |
| 2020 | Diet and the colonic exfoliome: a novel, non-invasive approach to testing interventions in humans1R21CA245456-01 | CHAPKIN, ROBERT STEPHENHULLAR, MEREDITHLAMPE, JOHANNA W | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $136,323 | ZCA1 |
| 2019 | Evaluating Novel Targeted Therapies in Cholangiocarcinoma Using Tumor Slice Cultures1R21CA231486-01A1 | SAHA, SUPRIYA K | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $242,562 | ZCA1 |
| 2019 | Novel Approach to CD33-Targeted Immunotherapy of Acute Myeloid Leukemia1R21CA234203-01 | WALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $236,741 | ZCA1 |
| 2019 | Metabolomics: Novel Strategies to Improve Breast Cancer Radiotherapy Responses1R21CA234880-01A1 | HU, JENNIFER J | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $233,704 | ZCA1 |
| 2019 | Identifying the missing link in inflammatory signaling1R56CA230069-01A1 | EISENMESSER, ELAN Z | UNIVERSITY OF COLORADO DENVER, CO | $233,250 | ZCA1 |
| 2019 | Novel anti-cancer biologics targeting Wnt signaling pathway1R21CA235533-01 | DONG, MINJIN, RONGSHENG | BOSTON CHILDREN'S HOSPITAL, MA | $233,051 | ZCA1 |
| 2019 | Study of Plasma Next Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients with ALK Drug Resistance (SPACEWALK)1R21CA234816-01 | OXNARD, GEOFFREY RAYMOND | DANA-FARBER CANCER INST, MA | $230,333 | ZCA1 |
| 2019 | "Combining radiation with TLR5 agonist based immunotherapy against liver metastases"1R21CA226463-01A1 | GUDKOV, ANDREI V | ROSWELL PARK CANCER INSTITUTE CORP, NY | $227,984 | ZCA1 |
| 2019 | scFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid Leukemia1R21CA223400-01A1 | YU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $225,765 | ZCA1 |
| 2019 | A Novel E3 Ubiquitin Ligase for CML Stem Cells1R21CA229967-01A1 | CHEN, WENYONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $225,765 | ZCA1 |
| 2019 | Identification of a prognostic and predictive glucocorticoid receptor signature for ovarian cancer1R21CA223426-01A1 | CONZEN, SUZANNE DANIELA | UNIVERSITY OF CHICAGO, IL | $225,023 | ZCA1 |
| 2019 | Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies1R21CA234519-01 | TAO, JIANGUO | H. LEE MOFFITT CANCER CTR & RES INST, FL | $224,460 | ZCA1 |
| 2019 | Developing a NF-κB/GADD45b targeting strategy for glioblastoma1R21CA222992-01A1 | BHAT, KRISHNA PL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $224,297 | ZCA1 |
| 2019 | Bronchoscopic Cryo-Immunotherapy of Lung Cancer1R21CA229714-01A1 | STERMAN, DANIEL | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $221,198 | ZCA1 |
| 2019 | Ponatinib Induces Vascular Events in CML-Mechanisms and Correction1R21CA223301-01A1 | SCHMAIER, ALVIN H | CASE WESTERN RESERVE UNIVERSITY, OH | $218,406 | ZCA1 |
| 2019 | Targeting EMP2 for the treatment of triple negative breast cancer with novel anti-EMP2 Granzyme B immunoconjugates1R21CA234642-01A1 | MOHAMEDALI, KHALID AWADEHRA, MADHURI | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $218,370 | ZCA1 |
| 2019 | Large-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy development1R21CA234775-01 | MAGER, DONALD EQU, JUNSTRAUBINGER, ROBERT M | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $218,284 | ZCA1 |
| 2019 | Identification of Epigenetic Regulators Mediating Resistance to FGFR Inhibition in Squamous Cell Carcinoma1R21CA226099-01A1 | RAMSEY, MATTHEW ROBERT | BRIGHAM AND WOMEN'S HOSPITAL, MA | $217,642 | ZCA1 |
| 2019 | Peptoid conjugates as inhibitors of androgen receptor dimerization and function in enzalutamide-resistant prostate cancer1R21CA234291-01A1 | GARABEDIAN, MICHAEL J.KIRSHENBAUM, KENT W | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $216,835 | ZCA1 |
| 2019 | Development of multiplex single cell phosphotyrosine profiling tools for B-cell malignancies1R21CA234824-01A1 | MACHIDA, KAZUYA | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $214,020 | ZCA1 |
| 2019 | Proton Therapy to Reduce Heart Damage for Lung Cancer Patients1R21CA222749-01A1 | LIAO, ZHONGXING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $211,410 | ZCA1 |
| 2019 | Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion1R21CA240881-01 | AL-ATRASH, GHEATHLIN, STEVEN HSESHENG | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $211,410 | ZCA1 |
| 2019 | FGFR4-CAR-based Immunotherapy of Fusion-Positive Rhabdomyosarcoma1R21CA241023-01 | ORENTAS, RIMAS J | SEATTLE CHILDREN'S HOSPITAL, WA | $210,572 | ZCA1 |
| 2019 | A 3D ex vivo orthotopic xenograft screening platform to identify radiosensitization targets and druggability in glioma1R21CA226483-01A1 | FLOYD, SCOTT R | DUKE UNIVERSITY, NC | $209,561 | ZCA1 |
| 2019 | Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma1R21CA234701-01 | KANG, YUBIN | DUKE UNIVERSITY, NC | $209,453 | ZCA1 |
| 2019 | Novel Targeting of Liver Cancer Deficient of DNA Repair1R21CA241025-01 | DU, CHUNYING | UNIVERSITY OF CINCINNATI, OH | $209,453 | ZCA1 |
| 2019 | Keratinocyte targeted strategies for treatment of cutaneous GVHD1R21CA223419-01A1 | CARDONES, ADELA RAMBIZHANG, JENNIFER YUNYAN | DUKE UNIVERSITY, NC | $209,344 | ZCA1 |
| 2019 | FoxM1 as a Novel Therapeutic Target to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma1R21CA234851-01 | WANG, MICHAEL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2019 | Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy1R21CA241001-01 | LIN, STEVEN HSESHENG | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2019 | Diagnostic biomarkers for hepatoblastomas with hepatocellular carcinoma features1R21CA223140-01A1 | SUMAZIN, PAVEL | BAYLOR COLLEGE OF MEDICINE, TX | $208,800 | ZCA1 |
| 2019 | Novel fluorinated amino ester prodrugs for PET imaging of gliomas1R21CA234764-01A1 | MCCONATHY, JONATHAN EDWARD | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2019 | Toward Changing Glioblastoma Outcomes: Targeted drug delivery of an inhibitory biopolymer in conjunction with systemic chemotherapy1R21CA229943-01A1 | RAUCHER, DRAZEN | UNIVERSITY OF MISSISSIPPI MED CTR, MS | $207,841 | ZCA1 |
| 2019 | Ecdysoneless, A Novel Regulator of Androgen Receptor1R21CA241055-01 | BAND, VIMLA | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $206,907 | ZCA1 |
| 2019 | Development of Antibody-RNAi Conjugates (ARCs) to Treat Lung Cancer1R21CA234740-01 | DOWDY, STEVEN F | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $205,157 | ZCA1 |
| 2019 | Utilizing microRNA-146a to Block Triple-Negative Breast Cancer Cell Colonization1R56CA223077-01A1 | LIU, RUNHUA RUNA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $204,188 | ZCA1 |
| 2019 | A novel sustained-release immunotoxin for treatment of glioblastoma multiforme1R21CA237705-01 | CHILKOTI, ASHUTOSH | DUKE UNIVERSITY, NC | $203,646 | ZCA1 |
| 2019 | A phase 0 pilot study to determine if papaverine increases oxygenation in spontaneous canine soft tissue sarcoma1R21CA226477-01A1 | DENKO, NICHOLAS C. | OHIO STATE UNIVERSITY, OH | $203,580 | ZCA1 |
| 2019 | Combatting Bladder Cancer by Inducing Epithelial Turnover1R21CA223093-01A1 | ABRAHAM, SOMAN N | DUKE UNIVERSITY, NC | $203,510 | ZCA1 |
| 2019 | Targeting and Delivering CAR-Ts in Glioblastoma1R21CA229938-01A1 | DOTTI, GIANPIETRO | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $202,928 | ZCA1 |
| 2019 | Phase 1 study to test safety and dose of proglumide as an anti-fibrotic agent1R21CA241007-01 | SMITH, JILL P | GEORGETOWN UNIVERSITY, DC | $202,928 | ZCA1 |
| 2019 | Novel Ultrasound Localization of Pulmonary Nodules during Video Assisted Thoracic Surgery to Improve Surgical Resection1R21CA231503-01A1 | EGAN, THOMAS M.MULLER, MARIE | NORTH CAROLINA STATE UNIVERSITY RALEIGH, NC | $202,525 | ZCA1 |
| 2019 | Chemical ablation of ductal tree for breast cancer prevention1R21CA226579-01A1 | SEMPERE, LORENZO | MICHIGAN STATE UNIVERSITY, MI | $202,275 | ZCA1 |
| 2019 | Small Molecule Inhibitors of a Reader of DNA Methylation1R21CA241005-01 | BUSHWELLER, JOHN HACKETT | UNIVERSITY OF VIRGINIA, VA | $201,929 | ZCA1 |
| 2019 | A diagnostic model for malignant pulmonary nodules1R21CA240556-01 | JIANG, FENG | UNIVERSITY OF MARYLAND BALTIMORE, MD | $201,623 | ZCA1 |
| 2019 | Development of clinically relevant models of DCIS1R21CA226542-01A1 | RIEGEL, ANNA TATE | GEORGETOWN UNIVERSITY, DC | $201,600 | ZCA1 |
| 2019 | Radiation therapy eliminating cancer by SIRPa depletion1R21CA241271-01 | LIU, YUAN | GEORGIA STATE UNIVERSITY, GA | $201,514 | ZCA1 |
| 2019 | Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer1R21CA234787-01A1 | ENDERLING, HEIKOGATENBY, ROBERT A | H. LEE MOFFITT CANCER CTR & RES INST, FL | $200,318 | ZCA1 |
| 2019 | Implication of a novel long noncoding RNA in therapy resistant prostate cancer with altered AR signaling1R21CA226611-01A1 | CHAKRABARTI, RATNA | UNIVERSITY OF CENTRAL FLORIDA, FL | $198,703 | ZCA1 |
| 2019 | Improving Lytic Potency of Herpes Virus Cancer Therapeutics1R21CA223104-01A1 | CRIPE, TIMOTHY PWANG, PIN YI | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $198,360 | ZCA1 |
| 2019 | A promising small molecule for pancreatic cancer therapy1R21CA234681-01 | SHARMA, ARUN K | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $198,064 | ZCA1 |
| 2019 | Novel four dimensional magnetic resonance imaging to monitor pancreatic tumor infiltrating blood vessels and tumor response to chemoradiation therapy1R21CA234637-01A1 | FAN, ZHAOYANGYANG, WENSHA | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $196,643 | ZCA1 |
| 2019 | Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.1R21CA216789-01A1 | BANERJEE, NILAM SANJIB | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $193,793 | ZCA1 |
| 2019 | Translation development of a novel therapeutic antibody against drug-resistant B-cell malignancies1R21CA223141-01A1 | QIN, HONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $188,138 | ZCA1 |
| 2019 | Novel Multiplex Biomarker Discovery Methods To Predict Breast Cancer Risk After A Benign Biopsy1R21CA234827-01 | SHERMAN, MARK E | MAYO CLINIC JACKSONVILLE, FL | $183,341 | ZCA1 |
| 2019 | Explore piRNA as a novel therapeutics for hepatocellular carcinoma1R21CA238100-01 | ZHU, YONG | YALE UNIVERSITY, CT | $182,156 | ZCA1 |
| 2019 | Armed oncolytic parvoviral vectors for modulating the tumor microenvironment1R21CA240166-01 | TATTERSALL, PETER J. | YALE UNIVERSITY, CT | $182,156 | ZCA1 |
| 2019 | An innovative modular strategy for highly specific elimination of human osteosarcomas1R21CA237505-01 | CRIPE, TIMOTHY PKUDRYASHOV, DMITRI | OHIO STATE UNIVERSITY, OH | $179,916 | ZCA1 |
| 2019 | Development of a Tryptic-Lectin ELISA for the early detection of HCC1R21CA234875-01A1 | MEHTA, ANAND S. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $177,263 | ZCA1 |
| 2019 | Therapeutic use of T cells engineered to produce radiation-inducible cytokines1R21CA226582-01A1 | WEICHSELBAUM, RALPH R | UNIVERSITY OF CHICAGO, IL | $176,175 | ZCA1 |
| 2019 | Targeting of CDK6 in Myelofibrosis1R21CA235472-01 | MOHI, GOLAM | UNIVERSITY OF VIRGINIA, VA | $175,631 | ZCA1 |
| 2019 | Therapeutic potential of Cpf1-based gene editing for myeloproliferative neoplasms1R21CA234866-01A1 | WU, WEN-SHU | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $173,891 | ZCA1 |
| 2019 | Leveraging MR-Guided Focused Ultrasound to Potentiate Immunotherapy for GBM1R21CA226607-01A1 | BULLOCK, TIMOTHY N | UNIVERSITY OF VIRGINIA, VA | $173,754 | ZCA1 |
| 2019 | Evaluation of PAK inhibitors towards targeting adaptive mechanisms of resistance in high-risk rhabdomyosarcoma1R21CA234665-01 | YUSTEIN, JASON | BAYLOR COLLEGE OF MEDICINE, TX | $172,369 | ZCA1 |
| 2019 | Targeted Phase-change Nanodroplets for Translatable Molecular Ultrasound Imaging of Micrometastases1R21CA234526-01 | BOUCHARD, RICHARD R. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $171,720 | ZCA1 |
| 2019 | Application of Mucolytic Therapy in Patient-Derived Models of Pseudomyxoma Peritonei1R21CA241004-01 | CHOUDRY, MOHAMMAD HAROON ASIF | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $170,194 | ZCA1 |
| 2019 | IMMUNE CHECKPOINT BLOCKADE PROMOTES ADULT T CELL LEUKEMIA1R21CA234640-01 | RATNER, LEE | WASHINGTON UNIVERSITY, MO | $169,786 | ZCA1 |
| 2019 | Surgical treatment of post-surgical mastectomy pain utilizing the regenerative peripheral nerve interface (RPNI)1R21CA234760-01 | BROWN, DAVID LAWRENCE | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $169,650 | ZCA1 |
| 2019 | Ultra-short circulating tumor DNA (uctDNA) for liquid biopsy of non-small cell lung cancer1R21CA239052-01 | LI, FENGWONG, DAVID T | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $169,650 | ZCA1 |
| 2019 | Evaluation of TP53 mutations in non-cancerous tissue as novel biomarkers of ovarian cancer risk.1R21CA240885-01 | RISQUES, ROSA ANA | UNIVERSITY OF WASHINGTON, WA | $169,106 | ZCA1 |
| 2019 | Does overexpression of DNA polymerase theta sensitize cancers to G-quadruplex binding drugs?1R21CA240875-01 | MEEK, KATHERYN D | MICHIGAN STATE UNIVERSITY, MI | $168,563 | ZCA1 |
| 2019 | Androgen Receptor-containing novel transcriptional complex for cancer-specific gene expression in therapy-resistant Prostate Cancer1R21CA241234-01 | DUTTA, SAMIKSHAN | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $165,844 | ZCA1 |
| 2019 | Identifying the precursor to hematopoietic stem cells in the mouse embryo and improving its engraftment upon transplantation1R21CA224022-01A1 | INLAY, MATTHEW A | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $159,308 | ZCA1 |
| 2019 | Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade glioma1R21CA233856-01 | OKADA, HIDEHO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $144,165 | ZCA1 |
| 2019 | Efficacy of Allosteric SHP2 Inhibitor in RAS Mutant-Driven Myeloid Neoplasms1R21CA242512-01 | MOHI, GOLAM | UNIVERSITY OF VIRGINIA, VA | $140,505 | ZCA1 |
| 2019 | Single-guide-RNA-directed Synergistic Activation Mediator, a novel strategy to sensitize Non-Hodgkin Lymphomas to therapeutic drugs.1R21CA238139-01 | KANDOUZ, MUSTAPHA | WAYNE STATE UNIVERSITY, MI | $100,485 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.